NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intellipharmaceutics International Inc. (“Intellipharmaceutics”) (NASDAQ: IPCI) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/IPCI-Request-Form-1663. There is no cost or obligation to you.
On July 26, 2017, Intellipharmaceutics disclosed that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration voted 22 to 1 that the New Drug Application for Rexista extended release tablets should not be approved at this time. In addition, the committees voted that Rexista has not demonstrated properties than can be expected to deter abuse by the intravenous route, and that there was insufficient data to support “inclusion of language regarding abuse-deterrent properties in the product label for the intravenous route of administration.” Following this news, shares of Intellipharmaceutics were down more than 41% on intraday dating on July 27, 2017.
To learn more about the investigation of Intellipharmaceutics contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/IPCI-Request-Form-1663.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.